UBS Group
MIRA icon

UBS Group’s MIRA Pharmaceuticals MIRA Stock Holding History

UBS Group’s Portfolio MIRA Stock Details MIRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.68K Sell
1,772
-4,684
-73% -$4.74K ﹤0.01% 9497
2026
Q1 		$6.91K Buy
6,456
+3,756
+139% +$4.71K ﹤0.01% 8641
2025
Q4 		$4.08K Buy
2,700
+2,484
+1,150% +$3.65K ﹤0.01% 8893
2025
Q3 		$294 Sell
216
-284
-57% -$412 ﹤0.01% 9757
2025
Q2 		$605 Buy
+500
New +$577 ﹤0.01% 9782
2024
Q3 		– Sell
-29,546
Closed -$18.8K – 9857
2024
Q2 		$18.8K Buy
29,546
+24,775
+519% +$20.4K ﹤0.01% 7340
2024
Q1 		$5.25K Buy
+4,771
New +$5.18K ﹤0.01% 7556
2023
Q4 		– Sell
-25
Closed -$116 – 9673
2023
Q3 		$116 Buy
+25
New +$143 ﹤0.01% 8849

Other funds holding MIRA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CSI
Cross Staff Investments Pittsford, New York $178M AUM 21.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
FAB
First American Bank Dundee, Illinois $1.79B AUM 30.35% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group's MIRA Position: Q2 2026 in Review

UBS Group reduced its MIRA Pharmaceuticals (MIRA) stake by 73% in Q2 2026, selling an estimated $4.74K and leaving 1,772 shares worth $1.68K. The position accounts for ﹤0.01% of the portfolio, ranked #9497.

UBS Group first reported a position in MIRA in Q3 2023 and has held it in 8 quarters since. The position peaked at $18.8K in Q2 2024. 26 funds tracked by Wall St. Rank hold MIRA as of Q2 2026.

  • UBS Group held 1,772 shares of MIRA Pharmaceuticals worth $1.68K as of Q2 2026.
  • UBS Group sold 4,684 MIRA Pharmaceuticals shares in Q2 2026, an estimated $4.74K.
  • MIRA Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9497 holding.
  • UBS Group first reported a position in MIRA Pharmaceuticals in Q3 2023 and has held it in 8 quarters since.
  • UBS Group's MIRA Pharmaceuticals position peaked at $18.8K in Q2 2024.
  • 26 funds tracked by Wall St. Rank held MIRA Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.